Literature DB >> 6156414

Amerioration of neurologic abnormalities after "enzyme replacement" in adenosine deaminase deficiency.

R Hirschhorn, P S Paageorgiou, H H Kesarwala, L T Taft.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6156414     DOI： 10.1056/NEJM198008143030706

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

1.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

2.  An abnormal amino acid pattern in adenosine deaminase deficiency.

Authors:  C Borrone; M Di Rocco; U Caruso; S Reali
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

3.  Homozygosity for a newly identified missense mutation in a patient with very severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).

Authors:  R Hirschhorn; V Chakravarti; J Puck; S D Douglas
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

4.  Parathyroid hormone-related protein, bone metastases and hypercalcaemia of malignancy.

Authors:  N J Bundred; J Walls; W A Ratcliffe
Journal:  Ann R Coll Surg Engl       Date:  1996-07       Impact factor: 1.891

5.  Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.

Authors:  H Ratech; M A Greco; G Gallo; D L Rimoin; H Kamino; R Hirschhorn
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

6.  Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

Authors:  J J Hutton; D A Wiginton; M S Coleman; S A Fuller; S Limouze; B C Lampkin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

7.  Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy.

Authors:  S L Sacks; T C Merigan; J Kaminska; I H Fox
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

Review 8.  How I treat ADA deficiency.

Authors:  H Bobby Gaspar; Alessandro Aiuti; Fulvio Porta; Fabio Candotti; Michael S Hershfield; Luigi D Notarangelo
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

9.  Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency.

Authors:  L D Notarangelo; G Stoppoloni; R Toraldo; E Mazzolari; A Coletta; P Airò; C Bordignon; A G Ugazio
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

10.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.